Related Experiment Videos
Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis
1St Patrick's Hospital, PO Box 136, James's Street, Dublin, Ireland.
Irish Journal of Medical Science
|March 20, 2004
Summary
Risperidone treatment was significantly less expensive than olanzapine for schizophrenia inpatients. This study compared the drug treatment costs of risperidone versus olanzapine in a real-world setting.
Area of Science:
- Pharmacoeconomics
- Psychiatry
- Schizophrenia Treatment
Background:
- Risperidone and olanzapine are atypical antipsychotics with comparable clinical efficacy.
- Understanding treatment costs is crucial for managing schizophrenia care.
Purpose of the Study:
- To compare the inpatient drug treatment costs of risperidone and olanzapine.
- To evaluate cost-effectiveness in a naturalistic setting for schizophrenia patients.
Main Methods:
- Retrospective review of medical records and prescriptions from 396 inpatients.
- Analysis of inpatient drug treatment costs, including daily and total expenses.
- Irish Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) programme.
Main Results:
- No significant difference in hospital stay duration between risperidone and olanzapine groups.
- Average daily and total inpatient drug costs were significantly higher for olanzapine.
- Mean daily doses: risperidone 4.2 mg, olanzapine 12.9 mg.
Conclusions:
- Risperidone treatment is associated with substantially lower drug costs compared to olanzapine.
- Cost implications favor risperidone in managing schizophrenia inpatient care.